Search results
Sep 16, 2024 · A monoclonal antibody developed by Eli Lilly to treat mild to moderate COVID-19, bamlanivimab is one of the drugs that Wohl and a team of researchers are studying through the ACTIV-2 clinical trial. “It means we’re on the right track,” Wohl says of the FDA’s November 9 emergency use authorization of the drug, the first to be issued for ...
Nov 16, 2020 · David Wohl, MD, is principal investigator for ACTIV-2, the COVID-19 treatments trial beginning at UNC . Last week’s authorization by the U.S. Food and Drug Administration for emergency use of bamlanivimab feels like a shot in the arm, so to speak, for David Wohl, MD, a UNC infectious diseases physician and researcher. A monoclonal antibody developed by Eli Lilly to
1 day ago · The Centers for Disease Control and Prevention said Friday that the E. coli outbreak linked to McDonald's has led to 75 cases across 13 states. Out of 61 patients with information available, 22 ...
14 hours ago · Fidelio is presented by the Washington National Opera on October 29, 2024, at 7:30 p.m., October 31 at 7:30p.m., November 2, 2024, at 7:00 pm and on November 4, 2024, at 7:00 pm at the Kennedy ...
May 27, 2024 · Washington mayor charged with sexual abuse. Kalen McCain. News Jan. 25, 2023 3:12 pm. A criminal complaint filed in the case Jan. 24 said the incident took place between Rosien and a 27-year-old ...
KCII Radio. 7,030 likes · 762 talking about this. We are committed to local news, local sports, and local information that keeps Washington, Iowa and surrounding areas informed. AM 1380 / 102.5 & FM...
Dr. Wohl is a Professor of Medicine in the Division of Infectious Diseases at the University of North Carolina (UNC). He is co-Principal Investigator of the Global UNC Infectious Diseases Clinical Trials Unit and Site Leader of its Chapel Hill research site. Dr. Wohl is a clinical scientist with a focus on emergent infectious diseases. He has ...
